Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

This article updates the Heart Failure Association of the European Society of Cardiology
(ESC) 2007 classification of advanced heart failure and describes new diagnostic and …

Importance Heart failure with reduced ejection fraction is a progressive clinical syndrome,
and many patients' condition worsen over time despite treatment. Patients with more severe …

Despite increasing prevalence in critical care units, cardiogenic shock related to HF (HF-CS)
is incompletely understood and distinct from acute myocardial infarction related CS. This …

ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Importance The mortality rate for the most advanced forms of heart failure with medical
therapy alone remains unacceptably high at 30% to 80% at 1 year. In the past decade, left …

Background Circulating microRNAs (miRs) are promising biomarkers for heart failure (HF).
Previous studies have provided inconsistent miR “signatures.” The phenotypic and …

Background The ROADMAP study showed survival with improved functional status was
better with left ventricular assist device (LVAD) therapy compared with optimal medical …

Aims Heart failure (HF) is a chronic and progressive syndrome associated with a poor
prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the …

BACKGROUND The outlook for ambulatory patients with advanced heart failure (HF) and
the appropriate timing for left ventricular assist device (LVAD) or transplant remain uncertain …